Progress in understanding of the mechanisms underlying chronic inflammatory skin disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options with the primary goal of alleviating symptoms. In addition, this knowledge has the potential to inform on new strategies aimed at inducing deep and therapy-free remission, that is, disease modification, potentially impacting on associated comorbidities. However, to reach this goal, key areas require further exploration, including the definitions of disease modification and disease activity index, further understanding of disease mechanisms and systemic spillover effects, potential windows of opportunity, biomarkers for patient stratification and successful intervention, as well as appropriate study design. This Perspective article assesses the opportunities and challenges in the discovery and development of disease-modifying therapies for chronic inflammatory skin disorders.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Hay, R. J. et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J. Invest. Dermatol. 134, 1527–1534 (2014).
Plewig, G., French, L. E., Ruzicka, T., Kaufman, R. & Hertl, M. Braun-Falco’s Dermatology (Springer, 2022).
Boch, K. et al. Lichen planus. Front. Med. 8, 737813 (2021).
Kolkhir, P. et al. Urticaria. Nat. Rev. Dis. Prim. 8, 61 (2022).
Kolkhir, P. et al. Autoimmune chronic spontaneous urticaria. J. Allergy Clin. Immunol. 149, 1819–1831 (2022).
Sabat, R. et al. Hidradenitis suppurativa. Nat. Rev. Dis. Prim. 6, 18 (2020).
Boehncke, W. H. & Schon, M. P. Psoriasis. Lancet 386, 983–994 (2015).
Conrad, C. & Gilliet, M. Psoriasis: from pathogenesis to targeted therapies. Clin. Rev. Allergy Immunol. 54, 102–113 (2018).
Dainichi, T. et al. The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis. Nat. Immunol. 19, 1286–1298 (2018).
Bieber, T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat. Rev. Drug Discov. 21, 21–40 (2022).
Armstrong, A. W. et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 156, 258–269 (2020).
Weidinger, S. & Novak, N. Atopic dermatitis. Lancet 387, 1109–1122 (2016).
Stander, S. Atopic dermatitis. N. Engl. J. Med. 384, 1136–1143 (2021).
Bieber, T. Atopic dermatitis. N. Engl. J. Med. 358, 1483–1494 (2008).
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E. & Barker, J. Psoriasis. Lancet 397, 1301–1315 (2021).
Andersen, Y. M. F., Egeberg, A., Skov, L. & Thyssen, J. P. Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr. Dermatol. Rep. 6, 35–41 (2017).
Eckert, L. et al. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J. Am. Acad. Dermatol. 78, 54–61.e51 (2018).
Sandhu, J. K., Salame, N., Ehsani-Chimeh, N. & Armstrong, A. W. Economic burden of cutaneous infections in children and adults with atopic dermatitis. Pediatr. Dermatol. 36, 303–310 (2019).
Eckert, L., Gupta, S., Gadkari, A., Mahajan, P. & Gelfand, J. M. Burden of illness in adults with atopic dermatitis: analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J. Am. Acad. Dermatol. 81, 187–195 (2019).
Ismail, N. & Bray, N. Atopic dermatitis: economic burden and strategies for high-quality care. Br. J. Dermatol. 182, 1087–1088 (2020).
Weil, C. et al. Epidemiology and economic burden of atopic dermatitis: real-world retrospective data from a large nationwide Israeli healthcare provider database. Adv. Ther. 39, 2502–2514 (2022).
Vanderpuye-Orgle, J. et al. Evaluating the economic burden of psoriasis in the United States. J. Am. Acad. Dermatol. 72, 961–967.e5 (2015).
Wu, J. J. et al. Economic burden of comorbidities in patients with psoriasis in the USA. Dermatol. Ther. 13, 207–219 (2023).
Maintz, L. et al. Machine learning-based deep phenotyping of atopic dermatitis: severity-associated factors in adolescent and adult patients. JAMA Dermatol. 157, 1414–1424 (2021).
Silverberg, J. I. Comorbidities and the impact of atopic dermatitis. Ann. Allergy Asthma Immunol. 124, 144–151 (2019).
Kok, W. L., Yew, Y. W. & Thng, T. G. Comorbidities associated with severity of atopic dermatitis in young adult males: a national cohort study. Acta Derm. Venereol. 99, 652–656 (2019).
Thyssen, J. P., Skov, L., Hamann, C. R., Gislason, G. H. & Egeberg, A. Assessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index. J. Am. Acad. Dermatol. 76, 1088–1092.e1 (2017).
Davidson, W. F. et al. Report from the National Institute of Allergy and Infectious Diseases workshop on ‘Atopic dermatitis and the atopic march: mechanisms and interventions’. J. Allergy Clin. Immunol. 143, 894–913 (2019).
Takeshita, J. et al. Atopic dermatitis and the atopic march: considering racial and ethnic diversity in atopic disease progression. J. Allergy Clin. Immunol. 149, 1590–1591 (2022).
Han, H., Roan, F. & Ziegler, S. F. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol. Rev. 278, 116–130 (2017).
Khan, S. J., Dharmage, S. C., Matheson, M. C. & Gurrin, L. C. Is the atopic march related to confounding by genetics and early-life environment? A systematic review of sibship and twin data. Allergy 73, 17–28 (2018).
Egeberg, A., Andersen, Y. M., Gislason, G. H., Skov, L. & Thyssen, J. P. Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis. Allergy 72, 783–791 (2017).
Andersen, Y. M. F. et al. Poor agreement in questionnaire-based diagnostic criteria for adult atopic dermatitis is a challenge when examining cardiovascular comorbidity. Allergy 73, 923–931 (2017).
Villani, A. P. et al. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. Allergy 76, 3107–3121 (2021).
Ivert, L. U. et al. Association between atopic dermatitis and cardiovascular disease: a nationwide register-based case–control study from Sweden. Acta Derm. Venereol. 99, 865–870 (2019).
Mohan, G. C. & Silverberg, J. I. Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 151, 522–528 (2015).
Drucker, A. M. et al. Incident alopecia areata and vitiligo in adult women with atopic dermatitis: nurses’ health study 2. Allergy 72, 831–834 (2017).
Silverberg, J. I. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin. Dermatol. 35, 360–366 (2017).
Thyssen, J. P. et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy 73, 214–220 (2018).
Ayasse, M. T., Buddenkotte, J., Alam, M. & Steinhoff, M. Role of neuroimmune circuits and pruritus in psoriasis. Exp. Dermatol. 29, 414–426 (2020).
Mendonca, J. A., Aydin, S. Z. & D’Agostino, M. A. The use of ultrasonography in the diagnosis of nail disease among patients with psoriasis and psoriatic arthritis: a systematic review. Adv. Rheumatol. 59, 41 (2019).
Gisondi, P., Bellinato, F., Girolomoni, G. & Albanesi, C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front. Pharmacol. 11, 117 (2020).
Saleem, M. D., Kesty, C. & Feldman, S. R. Relative versus absolute risk of comorbidities in patients with psoriasis. J. Am. Acad. Dermatol. 76, 531–537 (2017).
Boehncke, W. H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front. Immunol. 9, 579 (2018).
Armstrong, A. W. & Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. J. Am. Med. Assoc. 323, 1945–1960 (2020).
Boehncke, W. H., Boehncke, S., Tobin, A. M. & Kirby, B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp. Dermatol. 20, 303–307 (2011).
Su, Y. S. et al. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy. J. Eur. Acad. Dermatol. Venereol. 27, 876–883 (2013).
Boehner, A., Navarini, A. A. & Eyerich, K. Generalized pustular psoriasis — a model disease for specific targeted immunotherapy, systematic review. Exp. Dermatol. 27, 1067–1077 (2018).
Navarini, A. A. et al. European consensus statement on phenotypes of pustular psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1792–1799 (2017).
Misiak-Galazka, M., Wolska, H. & Rudnicka, L. Is palmoplantar pustulosis simply a variant of psoriasis or a distinct entity? J. Eur. Acad. Dermatol. Venereol. 31, e342–e343 (2017).
de Waal, A. C. & van de Kerkhof, P. C. Pustulosis palmoplantaris is a disease distinct from psoriasis. J. Dermatol. Treat. 22, 102–105 (2011).
Puig, L. et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals, and disease management. J. Eur. Acad. Dermatol. Venereol. 37, 737–752 (2023).
Zheng, M., Jullien, D. & Eyerich, K. The prevalence and disease characteristics of generalized pustular psoriasis. Am. J. Clin. Dermatol. 23, 5–12 (2022).
Reynolds, K. A. et al. Generalized pustular psoriasis: a review of the pathophysiology, clinical manifestations, diagnosis, and treatment. Cutis 110, 19–25 (2022).
van de Kerkhof, P. C. Biologics for psoriasis: maintenance treatment and true disease modification. J. Dermatol. Treat. 28, 281 (2017).
Bieber, T., Cork, M. & Reitamo, S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 67, 969–975 (2012).
Heath, W. R. & Carbone, F. R. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat. Immunol. 14, 978–985 (2013).
Pasparakis, M., Haase, I. & Nestle, F. O. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14, 289–301 (2014).
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K. & Irvine, A. D. Atopic dermatitis. Nat. Rev. Dis. Prim. 4, 1 (2018).
Nosbaum, A. et al. Psoriasis is a disease of the entire skin: non-lesional skin displays a prepsoriasis phenotype. Eur. J. Dermatol. 31, 143–154 (2021).
Zhang, Q. & Cao, X. Epigenetic remodeling in innate immunity and inflammation. Annu. Rev. Immunol. 39, 279–311 (2021).
Crowl, J. T. et al. Tissue-resident memory CD8(+) T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments. Nat. Immunol. 23, 1121–1131 (2022).
Luong, T. M. H. & Buggert, M. Tissue-specific epigenomics of resident memory CD8(+) T cells. Nat. Rev. Immunol. 22, 533 (2022).
Naik, S. & Fuchs, E. Inflammatory memory and tissue adaptation in sickness and in health. Nature 607, 249–255 (2022).
Brunner, P. M. et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J. Invest. Dermatol. 137, 18–25 (2017).
Thijs, J. L. et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. J. Allergy Clin. Immunol. 141, 1523–1526 (2018).
Ryan, C. & Kirby, B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol. Clin. 33, 41–55 (2015).
Christophers, E. & van de Kerkhof, P. C. M. Severity, heterogeneity and systemic inflammation in psoriasis. J. Eur. Acad. Dermatol. Venereol. 33, 643–647 (2019).
Korman, N. J. Management of psoriasis as a systemic disease: what is the evidence? Br. J. Dermatol. 182, 840–848 (2020).
Demehri, S., Morimoto, M., Holtzman, M. J. & Kopan, R. Skin-derived TSLP triggers progression from epidermal-barrier defects to asthma. PLoS Biol. 7, e1000067 (2009).
Siracusa, M. C. et al. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature 477, 229–233 (2011).
Zhu, Z., Oh, M. H., Yu, J., Liu, Y. J. & Zheng, T. The role of TSLP in IL-13-induced atopic march. Sci. Rep. 1, 23 (2011).
Yamanaka, K. & Mizutani, H. ‘Inflammatory skin march’: IL-1-mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events. J. Allergy Clin. Immunol. 136, 823–824 (2015).
Saunders, S. P. et al. Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. J. Allergy Clin. Immunol. 137, 482–491 (2016).
Yi, L. et al. Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis. Mucosal Immunol. 10, 1491–1503 (2017).
Furue, M. & Kadono, T. ‘Inflammatory skin march’ in atopic dermatitis and psoriasis. Inflamm. Res. 66, 833–842 (2017).
He, H. et al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. J. Allergy Clin. Immunol. 147, 1369–1380 (2021).
Maintz, L., Bieber, T., Simpson, H. D. & Demessant-Flavigny, A. L. From skin barrier dysfunction to systemic impact of atopic dermatitis: implications for a precision approach in dermocosmetics and medicine. J. Pers. Med. 12, 893 (2022).
Neimann, A. L. et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 55, 829–835 (2006).
Gelfand, J. M. et al. Risk of myocardial infarction in patients with psoriasis. J. Am. Med. Assoc. 296, 1735–1741 (2006).
Mehta, N. N. et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am. J. Med. 124, 775.e1–6 (2011).
Egeberg, A. et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J. Am. Acad. Dermatol. 77, 650–656.e3 (2017).
Buffum, W. P. & Settipane, G. A. Prognosis of asthma in childhood. Am. J. Dis. Child. 112, 214–217 (1966).
Gordon, B. R. The allergic march: can we prevent allergies and asthma? Otolaryngol. Clin. North Am. 44, 765–777 (2011).
van der Hulst, A. E., Klip, H. & Brand, P. L. Risk of developing asthma in young children with atopic eczema: a systematic review. J. Allergy Clin. Immunol. 120, 565–569 (2007).
Gustafsson, D., Sjoberg, O. & Foucard, T. Development of allergies and asthma in infants and young children with atopic dermatitis — a prospective follow-up to 7 years of age. Allergy 55, 240–245 (2000).
Suarez-Farinas, M. et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 127, 954–964 (2011).
Brunner, P. M. et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. Allergy 72, 2017–2025 (2017).
Leung, D. Y. M. et al. The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype. Sci. Transl. Med. 11, eaav2685 (2019).
Pavel, A. B. et al. Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy 76, 314–325 (2021).
Renert-Yuval, Y. et al. Tape strips capture atopic dermatitis-related changes in nonlesional skin throughout maturation. Allergy 77, 3445–3447 (2022).
Renert-Yuval, Y. et al. Biomarkers in atopic dermatitis — a review on behalf of the International Eczema Council. J. Allergy Clin. Immunol. 147, 1174–1190.e1 (2021).
Maintz, L. et al. IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype–phenotype associations in atopic dermatitis. Allergy https://doi.org/10.1111/all.15647 (2023).
Cummings, J. L. Measuring disease modification in Alzheimer’s disease. CNS Spectr. 12, 11–14 (2007).
Vellas, B., Andrieu, S., Sampaio, C. & Wilcock, G., European Task Force Group. Disease-modifying trials in Alzheimer’s disease: a European task force consensus. Lancet Neurol. 6, 56–62 (2007).
Citron, M. Alzheimer’s disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387–398 (2010).
Cummings, J. Disease modification and neuroprotection in neurodegenerative disorders. Transl. Neurodegener. 6, 25 (2017).
Liu-Seifert, H. et al. Disease modification in Alzheimer’s disease: current thinking. Ther. Innov. Regul. Sci. 54, 396–403 (2020).
Smedinga, M., Darweesh, S. K. L., Bloem, B. R., Post, B. & Richard, E. Towards early disease modification of Parkinson’s disease: a review of lessons learned in the Alzheimer field. J. Neurol. 268, 724–733 (2021).
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson’s disease. Lancet Neurol. 20, 559–572 (2021).
Cross, J. H. & Lagae, L. The concept of disease modification. Eur. J. Paediatr. Neurol. 24, 43–46 (2020).
Russo, E. & Citraro, R. Disease modification in epilepsy: behavioural accompaniments. Curr. Top. Behav. Neurosci. 55, 145–167 (2022).
Klitgaard, H. & Pitkanen, A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disord. 5, S9–S16 (2003).
French, J. A. et al. Antiepileptogenesis and disease modification: clinical and regulatory issues. Epilepsia Open 6, 483–492 (2021).
Hanly, J. G. & Lethbridge, L. Use of disease-modifying antirheumatic drugs, biologics, and corticosteroids in older patients with rheumatoid arthritis over 20 years. J. Rheumatol. 48, 977–984 (2021).
Abramson, S. B., Attur, M. & Yazici, Y. Prospects for disease modification in osteoarthritis. Nat. Clin. Pract. Rheumatol. 2, 304–312 (2006).
Oo, W. M. & Hunter, D. J. Disease modification in osteoarthritis: are we there yet? Clin. Exp. Rheumatol. 37, 135–140 (2019).
Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745–1759 (2019).
Nagaraja, V. et al. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis Rheumatol. 72, 1049–1058 (2020).
Segaert, S. et al. Long-term topical management of psoriasis: the road ahead. J. Dermatol. Treat. 33, 111–120 (2022).
Yasmeen, N. et al. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. J. Dermatol. Treat. 33, 204–218 (2022).
Solmaz, D. et al. Evidence that systemic therapies for psoriasis may reduce psoriatic arthritis occurrence. Clin. Exp. Rheumatol. 38, 257–261 (2020).
Magina, S. & Filipe, P. Pathophysiology of moderate to severe plaque psoriasis: anti-IL-17 towards disease modification. Drugs Today 57, 347–357 (2021).
Ghoreschi, K., Balato, A., Enerback, C. & Sabat, R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397, 754–766 (2021).
Iversen, L. et al. Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification — rationale and design of the randomized, multicenter STEPIn study. J. Eur. Acad. Dermatol. Venereol. 32, 1930–1939 (2018).
Mahler, V. et al. Allergen immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation — summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019. Clin. Transl. Allergy 10, 28 (2020).
Bieber, T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 75, 54–62 (2020).
Tsoi, L. C. et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J. Invest. Dermatol. 139, 1480–1489 (2019).
Czarnowicki, T. et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J. Allergy Clin. Immunol. 145, 215–228 (2020).
Bieber, T. et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J. Allergy Clin. Immunol. 139, S58–S64 (2017).
Yew, Y. W., Thyssen, J. P. & Silverberg, J. I. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J. Am. Acad. Dermatol. 80, 390–401 (2019).
Wollenberg, A., Zoch, C., Wetzel, S., Plewig, G. & Przybilla, B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J. Am. Acad. Dermatol. 49, 198–205 (2003).
Hinz, T. et al. Atopic dermo-respiratory syndrome is a correlate of eczema herpeticum. Allergy 66, 925–933 (2011).
Belgrave, D. C. et al. Developmental profiles of eczema, wheeze, and rhinitis: two population-based birth cohort studies. PLoS Med. 11, e1001748 (2014).
Lee, E. et al. Atopic dermatitis phenotype with early onset and high serum IL-13 is linked to the new development of bronchial hyperresponsiveness in school children. Allergy 71, 692–700 (2016).
Wan, J. et al. Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: a cohort study. J. Am. Acad. Dermatol. 77, 634–640 (2017).
Roduit, C. et al. Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr. 171, 655–662 (2017).
Paternoster, L. et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J. Allergy Clin. Immunol. 141, 964–971 (2018).
Berna, R., Mitra, N., Hoffstad, O., Wan, J. & Margolis, D. J. Identifying phenotypes of atopic dermatitis in a longitudinal United States cohort using unbiased statistical clustering. J. Invest. Dermatol. 140, 477–479 (2020).
Garmhausen, D. et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 68, 498–506 (2013).
Irvine, A. D., McLean, W. H. & Leung, D. Y. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 365, 1315–1327 (2011).
Margolis, D. J. Atopic dermatitis: filaggrin and skin barrier dysfunction. Br. J. Dermatol. 186, 396 (2022).
Moitinho-Silva, L. et al. Host genetic factors related to innate immunity, environmental sensing and cellular functions are associated with human skin microbiota. Nat. Commun. 13, 6204 (2022).
Beaziz, J., Bouaziz, J. D., Jachiet, M., Fite, C. & Lons-Danic, D. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. Ann. Dermatol. Venereol. 148, 198–201 (2021).
Brumfiel, C. M., Patel, M. H. & Zirwas, M. J. Development of psoriasis during treatment with dupilumab: a systematic review. J. Am. Acad. Dermatol. 86, 708–709 (2022).
Bridgewood, C. et al. T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. J. Invest. Dermatol. 142, 2660–2667 (2022).
Geba, G. P. et al. Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. J. Allergy Clin. Immunol. 151, 756–766 (2023).
Bieber, T. In search of the Holy Grail in atopic dermatitis: will dupilumab become the first disease-modifying atopic dermatitis drug? J. Allergy Clin. Immunol. 151, 694–696 (2023).
Bantz, S. K., Zhu, Z. & Zheng, T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J. Clin. Cell Immunol. 5, 202 (2014).
Westman, M., Asarnoj, A., Hamsten, C., Wickman, M. & van Hage, M. Windows of opportunity for tolerance induction for allergy by studying the evolution of allergic sensitization in birth cohorts. Semin. Immunol. 30, 61–66 (2017).
Renz, H. et al. The neonatal window of opportunity-early priming for life. J. Allergy Clin. Immunol. 141, 1212–1214 (2018).
Noda, S. et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J. Allergy Clin. Immunol. 136, 1254–1264 (2015).
Wen, H. C. et al. Serum from Asian patients with atopic dermatitis is characterized by T(H)2/T(H)22 activation, which is highly correlated with nonlesional skin measures. J. Allergy Clin. Immunol. 142, 324–328.e11 (2018).
Chan, T. C. et al. Atopic dermatitis in Chinese patients shows T(H)2/T(H)17 skewing with psoriasiform features. J. Allergy Clin. Immunol. 142, 1013–1017 (2018).
Brunner, P. M. & Guttman-Yassky, E. Racial differences in atopic dermatitis. Ann. Allergy Asthma Immunol. 122, 449–455 (2019).
Lang, C. C. V. et al. Evidence for different immune signatures and sensitization patterns in sub-Saharan African vs. Central European atopic dermatitis patients. J. Eur. Acad. Dermatol. Venereol. 35, e140–e142 (2021).
Biagini, J. M. et al. Longitudinal atopic dermatitis endotypes: an atopic march paradigm that includes Black children. J. Allergy Clin. Immunol. 149, 1702–1710.e4 (2022).
Illi, S. et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J. Allergy Clin. Immunol. 113, 925–931 (2004).
Peters, A. S. et al. Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study. J. Allergy Clin. Immunol. 126, 590–595 (2010).
Ballardini, N. et al. Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy 67, 537–544 (2012).
Margolis, D. J. et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. J. Allergy Clin. Immunol. 133, 784–789 (2014).
Berna, R. et al. Uncommon variants in FLG2 and TCHHL1 are associated with remission of atopic dermatitis in a large longitudinal US cohort. Arch. Dermatol. Res. 314, 953–959 (2022).
Nedoszytko, B. et al. Genetic and epigenetic aspects of atopic dermatitis. Int. J. Mol. Sci. 21, 6484 (2020).
Rindler, K. et al. Spontaneously resolved atopic dermatitis shows melanocyte and immune cell activation distinct from healthy control skin. Front. Immunol. 12, 630892 (2021).
Bangert, C. et al. Persistence of mature dendritic cells, T(H)2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Ralpha blockade. Sci. Immunol. 6, eabe2749 (2021).
Briot, A. et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J. Exp. Med. 206, 1135–1147 (2009).
Kennedy, E. A. et al. Skin microbiome before development of atopic dermatitis: early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year. J. Allergy Clin. Immunol. 139, 166–172 (2017).
Geoghegan, J. A., Irvine, A. D. & Foster, T. J. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol. 26, 484–497 (2018).
Paller, A. S. et al. The microbiome in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143, 26–35 (2019).
Harkins, C. P., Kong, H. H. & Segre, J. A. Manipulating the human microbiome to manage disease. J. Am. Med. Assoc. 323, 303–304 (2019).
Tham, E. H., Koh, E., Common, J. E. A. & Hwang, I. Y. Biotherapeutic approaches in atopic dermatitis. Biotechnol. J. 15, e1900322 (2020).
Cully, M. Microbiome therapeutics go small molecule. Nat. Rev. Drug Discov. 18, 569–572 (2019).
Myles, I. A. et al. Transplantation of human skin microbiota in models of atopic dermatitis. JCI Insight 1, e86955 (2016).
Nakatsuji, T. et al. Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial. Nat. Med. 27, 700–709 (2021).
Maura, D., Elmekki, N. & Goddard, C. A. The ammonia oxidizing bacterium Nitrosomonas eutropha blocks T helper 2 cell polarization via the anti-inflammatory cytokine IL-10. Sci. Rep. 11, 14162 (2021).
Nakatsuji, T. et al. Use of autologous bacteriotherapy to treat Staphylococcus aureus in patients with atopic dermatitis: a randomized double-blind clinical trial. JAMA Dermatol. 157, 978–982 (2021).
Brown, S. J., Elias, M. S. & Bradley, M. Genetics in atopic dermatitis: historical perspective and future prospects. Acta Derm. Venereol. 100, adv00163 (2020).
Simpson, E. L. et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J. Allergy Clin. Immunol. 134, 818–823 (2014).
Horimukai, K. et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J. Allergy Clin. Immunol. 134, 824–830.e6 (2014).
Kvenshagen, B. K., Carlsen, K. H., Mowinckel, P., Berents, T. L. & Carlsen, K. C. Can early skin care normalise dry skin and possibly prevent atopic eczema? A pilot study in young infants. Allergol. Immunopathol. 42, 539–543 (2014).
Chalmers, J. R. et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet 395, 962–972 (2020).
Skjerven, H. O. et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 395, 951–961 (2020).
Perrett, K. P. & Peters, R. L. Emollients for prevention of atopic dermatitis in infancy. Lancet 395, 923–924 (2020).
Lack, G. Update on risk factors for food allergy. J. Allergy Clin. Immunol. 129, 1187–1197 (2012).
Siegfried, E. C. et al. Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): draft guidance for industry. Pediatr. Dermatol. 35, 303–322 (2018).
Schneider, L. et al. Study of the atopic march: development of atopic comorbidities. Pediatr. Dermatol. 33, 388–398 (2016).
Arkin, M. R., Tang, Y. & Wells, J. A. Small-molecule inhibitors of protein–protein interactions: progressing toward the reality. Chem. Biol. 21, 1102–1114 (2014).
Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug Discov. 15, 533–550 (2016).
Majumdar, S., Ghosh, A. & Saha, S. Modulating interleukins and their receptors interactions with small chemicals using in silico approach for asthma. Curr. Top. Med. Chem. 18, 1123–1134 (2018).
Leyva-Castillo, J. M., Hener, P., Jiang, H. & Li, M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J. Invest. Dermatol. 133, 154–163 (2013).
Yang, N., Chen, Z., Zhang, X. & Shi, Y. Novel targeted biological agents for the treatment of atopic dermatitis. BioDrugs 35, 401–415 (2021).
Maurer, M. et al. Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis. J. Allergy Clin. Immunol. 150, 1517–1524 (2022).
Schuler, C. F. T. & Gudjonsson, J. E. IL-33 antagonism does not improve chronic atopic dermatitis: what can we learn? J. Allergy Clin. Immunol. 150, 1410–1411 (2022).
Spergel, J. M. et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J. Clin. Invest. 101, 1614–1622 (1998).
Brown, S. J. et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J. Allergy Clin. Immunol. 127, 661–667 (2011).
Guttman-Yassky, E. et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet 401, 204–214 (2023).
Le, A. M. & Torres, T. OX40-OX40L inhibition for the treatment of atopic dermatitis — focus on rocatinlimab and amlitelimab. Pharmaceutics 14, 2753 (2022).
Blom, L. H. et al. The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses. Allergy 72, 1081–1090 (2017).
Kotwica-Mojzych, K., Jodlowska-Jedrych, B. & Mojzych, M. CD200:CD200R interactions and their importance in immunoregulation. Int. J. Mol. Sci. 22, 1602 (2021).
Dixit, N. et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J. Transl. Autoimmun. 4, 100103 (2021).
Czarnowicki, T. et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J. Allergy Clin. Immunol. 136, 941–951.e943 (2015).
Esaki, H. et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J. Allergy Clin. Immunol. 138, 1639–1651 (2016).
Brunner, P. M. et al. Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. Ann. Allergy Asthma Immunol. 122, 318–330.e3 (2019).
Zhou, L. et al. Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 144, 144–156 (2019).
Bieber, T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 75, 54–62 (2020).
Bao, K. & Reinhardt, R. L. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine 75, 25–37 (2015).
Brunner, P. M. et al. Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. J. Allergy Clin. Immunol. 143, 142–154 (2019).
Padhi, A. et al. IL-22 downregulates peptidylarginine deiminase-1 in human keratinocytes: adding another piece to the IL-22 puzzle in epidermal barrier formation. J. Invest. Dermatol. 142, 333–342.e6 (2022).
Nakajima, S. et al. IL-17A as an inducer for Th2 immune responses in murine atopic dermatitis models. J. Invest. Dermatol. 134, 2122–2130 (2014).
Floudas, A. et al. IL-17 receptor a maintains and protects the skin barrier to prevent allergic skin inflammation. J. Immunol. 199, 707–717 (2017).
Topal, F. A., Zuberbier, T., Makris, M. P. & Hofmann, M. The role of IL-17, IL-23 and IL-31, IL-33 in allergic skin diseases. Curr. Opin. Allergy Clin. Immunol. 20, 367–373 (2020).
Hofmann, M. A. et al. Role of IL-17 in atopy — a systematic review. Clin. Transl. Allergy 11, e12047 (2021).
Sims, J. T. et al. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease. Exp. Dermatol. 30, 1650–1661 (2021).
Schwartz, D. M. et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 16, 843–862 (2017).
Gadina, M. et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology 58, i4–i16 (2019).
Tanaka, Y., Luo, Y., O’Shea, J. J. & Nakayamada, S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat. Rev. Rheumatol. 18, 133–145 (2022).
Ogawa, K. & Okada, Y. The current landscape of psoriasis genetics in 2020. J. Dermatol. Sci. 99, 2–8 (2020).
Tsai, Y. C. & Tsai, T. F. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. Int. J. Mol. Sci. 23, 5518 (2022).
Luo, Y. et al. Epigenetics in psoriasis: perspective of DNA methylation. Mol. Genet. Genom. 296, 1027–1040 (2021).
Shao, S. & Gudjonsson, J. E. Epigenetics of psoriasis. Adv. Exp. Med. Biol. 1253, 209–221 (2020).
Greb, J. E. et al. Psoriasis. Nat. Rev. Dis. Prim. 2, 16082 (2016).
Dand, N. et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J. Allergy Clin. Immunol. 143, 2120–2130 (2019).
Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41, 199–204 (2009).
Tang, H. et al. A large-scale screen for coding variants predisposing to psoriasis. Nat. Genet. 46, 45–50 (2014).
Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273–290 (2007).
Dand, N. et al. Psoriasis and genetics. Acta Derm. Venereol. 100, adv00030 (2020).
Schon, M. P. & Erpenbeck, L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front. Immunol. 9, 1323 (2018).
Bridgewood, C., Newton, D., Bragazzi, N., Wittmann, M. & McGonagle, D. Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis. Semin. Immunol. 58, 101520 (2021).
Bugaut, H. & Aractingi, S. Major role of the IL17/23 axis in psoriasis supports the development of new targeted therapies. Front. Immunol. 12, 621956 (2021).
Iznardo, H. & Puig, L. Dual inhibition of IL-17A and IL-17F in psoriatic disease. Ther. Adv. Chron. Dis. 12, 20406223211037846 (2021).
Blauvelt, A. & Chiricozzi, A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin. Rev. Allergy Immunol. 55, 379–390 (2018).
Cheuk, S. et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J. Immunol. 192, 3111–3120 (2014).
Ryan, G. E., Harris, J. E. & Richmond, J. M. Resident memory T cells in autoimmune skin diseases. Front. Immunol. 12, 652191 (2021).
Matos, T. R. et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones. J. Clin. Invest. 127, 4031–4041 (2017).
Tokura, Y., Phadungsaksawasdi, P., Kurihara, K., Fujiyama, T. & Honda, T. Pathophysiology of skin resident memory T cells. Front. Immunol. 11, 618897 (2020).
Suarez-Farinas, M., Fuentes-Duculan, J., Lowes, M. A. & Krueger, J. G. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J. Invest. Dermatol. 131, 391–400 (2011).
Oliver, R. et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br. J. Dermatol. 186, 652–663 (2022).
Whitley, S. K. et al. Local IL-23 is required for proliferation and retention of skin-resident memory T(H)17 cells. Sci. Immunol. 7, eabq3254 (2022).
Conrad, C. et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13, 836–842 (2007).
Patrick, M. T. et al. Causal relationship and shared genetic loci between psoriasis and type 2 diabetes through trans-disease meta-analysis. J. Invest. Dermatol. 141, 1493–1502 (2021).
Papp, K. A., Gooderham, M. J., Girard, G., Raman, M. & Strout, V. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 31, 1324–1332 (2017).
van de Kerkhof, P. C. From empirical to pathogenesis-based treatments for psoriasis. J. Invest. Dermatol. 142, 1778–1785 (2022).
Gordon, K. B. et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J. Invest. Dermatol. 139, 2437–2446.e1 (2019).
Blauvelt, A. et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br. J. Dermatol. 172, 484–493 (2015).
Strober, B. et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial. J. Am. Acad. Dermatol. 88, 40–51 (2023).
Eyerich, S. et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N. Engl. J. Med. 365, 231–238 (2011).
Bose, R. & Beecker, J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report. SAGE Open. Med. Case Rep. 8, 2050313X20904561 (2020).
Al-Janabi, A. et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J. Eur. Acad. Dermatol. Venereol. 34, 1440–1448 (2020).
Cohen, J. N., Bowman, S., Laszik, Z. G. & North, J. P. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: a retrospective study of T helper type 2 and 17 subsets, interleukin 36, and beta-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor alpha inhibitor-associated dermatitis. J. Am. Acad. Dermatol. 82, 430–439 (2020).
Strober, B. et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J. Am. Acad. Dermatol. 87, 800–806 (2022).
Mooney, N. et al. Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in vitro. J. Investig. Dermatol. 142, B26 (2022).
Golbari, N. M. et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J. Eur. Acad. Dermatol. Venereol. 35, 417–421 (2021).
Pinter, A., Gerdes, S., Papavassilis, C. & Reinhardt, M. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J. Dermatol. Treat. 31, 769–775 (2020).
Girolomoni, G. et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J. Dermatol. Treat. 26, 103–112 (2015).
Nell, V. P. et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 43, 906–914 (2004).
Quinn, M. A. & Cox, S. The evidence for early intervention. Rheum. Dis. Clin. North Am. 31, 575–589 (2005).
Anderson, J. J., Wells, G., Verhoeven, A. C. & Felson, D. T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 43, 22–29 (2000).
D’Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371, 660–667 (2008).
Trojano, M. et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann. Neurol. 66, 513–520 (2009).
Eyerich, K. et al. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open 11, e049822 (2021).
Simon, D. et al. Association of structural entheseal lesions with an increased risk of progression from psoriasis to psoriatic arthritis. Arthritis Rheumatol. 74, 253–262 (2022).
Garshick, M. S. et al. Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler. Thromb. Vasc. Biol. 39, 787–798 (2019).
Gottlieb, A. & Merola, J. F. Psoriatic arthritis for dermatologists. J. Dermatol. Treat. 31, 662–679 (2020).
Gisondi, P. et al. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis 12, 213–220 (2022).
Rosenthal, Y. S., Schwartz, N., Sagy, I. & Pavlovsky, L. Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case–control study. Arthritis Rheumatol. 74, 237–243 (2022).
Acosta Felquer, M. L. et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann. Rheum. Dis. 81, 74–79 (2022).
Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045–1050 (2015).
Creamer, J. D. & Barker, J. N. Vascular proliferation and angiogenic factors in psoriasis. Clin. Exp. Dermatol. 20, 6–9 (1995).
Weber, B. et al. Psoriasis and cardiovascular disease: novel mechanisms and evolving therapeutics. Curr. Atheroscler. Rep. 23, 67 (2021).
Kimball, A. B. et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology 217, 27–37 (2008).
Garshick, M. S., Ward, N. L., Krueger, J. G. & Berger, J. S. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J. Am. Coll. Cardiol. 77, 1670–1680 (2021).
Rose, S. et al. A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study. Am. J. Cardiovasc. Dis. 3, 273–278 (2013).
Zhou, W. et al. Association among noncalcified coronary burden, fractional flow reserve, and myocardial injury in psoriasis. J. Am. Heart Assoc. 9, e017417 (2020).
Ahlehoff, O. et al. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study. J. Eur. Acad. Dermatol. Venereol. 30, 819–823 (2016).
Wu, J. J. et al. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J. Am. Acad. Dermatol. 76, 81–90 (2017).
Armstrong, A. W. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients? J. Am. Med. Assoc. 309, 2043–2044 (2013).
Gelfand, J. M. et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J. Invest. Dermatol. 140, 85–93.e2 (2020).
Garshick, M. S. et al. A randomized open-label clinical trial of lipid-lowering therapy in psoriasis to reduce vascular endothelial inflammation. J. Invest. Dermatol. 142, 1749–1752.e4 (2022).
Garshick, M. S. & Berger, J. S. Psoriasis and cardiovascular disease — an ounce of prevention is worth a pound of cure. JAMA Dermatol. 158, 239–241 (2022).
Dyjack, N. et al. Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2-high atopic dermatitis disease endotype. J. Allergy Clin. Immunol. 141, 1298–1309 (2018).
Ungar, B. et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J. Invest. Dermatol. 137, 603–613 (2017).
He, H. et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J. Allergy Clin. Immunol. 147, 199–212 (2021).
Maintz, L., Bieber, T., Bissonnette, R. & Jack, C. Measuring atopic dermatitis disease severity: the potential for electronic tools to benefit clinical care. J. Allergy Clin. Immunol. Pract. 9, 1473–1486.e2 (2021).
Peyrin-Biroulet, L., Loftus, E. V. Jr, Colombel, J. F. & Sandborn, W. J. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut 59, 141–147 (2010).
Colombel, J. F., Louis, E., Peyrin-Biroulet, L., Sandborn, W. J. & Panaccione, R. Deep remission: a new concept? Dig. Dis. 30, 107–111 (2012).
Allen, P. B. & Peyrin-Biroulet, L. Moving towards disease modification in inflammatory bowel disease therapy. Curr. Opin. Gastroenterol. 29, 397–404 (2013).
Hanauer, S. B. Disease modification in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 10, 954–955 (2012).
Abuabara, K., Margolis, D. J. & Langan, S. M. The long-term course of atopic dermatitis. Dermatol. Clin. 35, 291–297 (2017).
Wan, J., Mitra, N., Hoffstad, O. J., Yan, A. C. & Margolis, D. J. Longitudinal atopic dermatitis control and persistence vary with timing of disease onset in children: a cohort study. J. Am. Acad. Dermatol. 81, 1292–1299 (2019).
Bieber, T. et al. Unraveling the complexity of atopic dermatitis: the CK-CARE approach toward precision medicine. Allergy 75, 2936–2938 (2020).
Thijs, J. L. et al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. J. Allergy Clin. Immunol. 140, 730–737 (2017).
van der Schaft, J., Thijs, J. L., Garritsen, F. M., Balak, D. & de Bruin-Weller, M. S. Towards personalized treatment in atopic dermatitis. Exp. Opin. Biol. Ther. 19, 469–476 (2019).
Koschitzky, M. et al. Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris. Exp. Dermatol. 31, 1341–1351 (2022).
Tsakok, T. et al. Association of serum ustekinumab levels with clinical response in psoriasis. JAMA Dermatol. 155, 1235–1243 (2019).
Foulkes, A. C. et al. A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis. J. Invest. Dermatol. 139, 100–107 (2019).
Lee, Y. H. & Song, G. G. Association between circulating prolactin levels and psoriasis and its correlation with disease severity: a meta-analysis. Clin. Exp. Dermatol. 43, 27–35 (2018).
Eyerich, K. et al. Human and computational models of atopic dermatitis: a review and perspectives by an expert panel of the International Eczema Council. J. Allergy Clin. Immunol. 143, 36–45 (2019).
Vetrano, S. et al. ImmUniverse Consortium: multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases. Front. Immunol. 13, 1002629 (2022).
Broderick, C. et al. Biomarkers associated with the development of comorbidities in patients with atopic dermatitis: a systematic review. Allergy 78, 84–120 (2023).
Ziehfreund, S. et al. Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021 — a two-round Delphi survey among international experts. J. Eur. Acad. Dermatol. Venereol. 36, 1467–1476 (2022).
Lee, J. W., Wu, Y. & Wang, J. Fit-for-purpose method validation and assays for biomarker characterization to support drug development. in Biomarkers in Drug Development (eds Bleavins, M. R., Carini, C., Jurima-Romet, M. & Rahbari, R.) 187–213 (Wiley, 2010).
Bieber, T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 67, 1475–1482 (2012).
Yu, K., Syed, M. N., Bernardis, E. & Gelfand, J. M. Machine learning applications in the evaluation and management of psoriasis: a systematic review. J. Psoriasis Psoriatic Arthritis 5, 147–159 (2020).
Patrick, M. T. et al. Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. Nat. Commun. 9, 4178 (2018).
Clausen, M. L., Slotved, H. C., Krogfelt, K. A. & Agner, T. Tape stripping technique for stratum corneum protein analysis. Sci. Rep. 6, 19918 (2016).
Rinaldi, A. O. et al. Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis. Allergy 76, 3066–3079 (2021).
Rinnov, M. R. et al. Skin biomarkers predict development of atopic dermatitis in infancy. Allergy 78, 791–802 (2023).
Kelsell, D. P. & Byrne, C. SNPing at the epidermal barrier. J. Invest. Dermatol. 131, 1593–1595 (2011).
Smieszek, S. P. et al. Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status. Sci. Rep. 10, 2721 (2020).
Kothekar, E. et al. Utility of FDG-PET/CT in clinical psoriasis grading: the PET-PASI scoring system. Am. J. Nucl. Med. Mol. Imaging 10, 265–271 (2020).
Seifert, R., Weber, M., Kocakavuk, E., Rischpler, C. & Kersting, D. Artificial intelligence and machine learning in nuclear medicine: future perspectives. Semin. Nucl. Med. 51, 170–177 (2021).
Rajpurkar, P., Chen, E., Banerjee, O. & Topol, E. J. AI in health and medicine. Nat. Med. 28, 31–38 (2022).
Elnabawi, Y. A. et al. CCL20 in psoriasis: a potential biomarker of disease severity, inflammation, and impaired vascular health. J. Am. Acad. Dermatol. 84, 913–920 (2021).
Garshick, M. S. et al. Characterization of PCSK9 in the blood and skin of psoriasis. J. Invest. Dermatol. 141, 308–315 (2021).
Zabotti, A., Tinazzi, I., Aydin, S. Z. & McGonagle, D. From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention. Curr. Rheumatol. Rep. 22, 24 (2020).
Gutierrez, M. et al. Subclinical entheseal involvement in patients with psoriasis: an ultrasound study. Semin. Arthritis Rheum. 40, 407–412 (2011).
Vyas, K. et al. Sonographic evaluation of subclinical enthesopathy in patients of chronic plaque psoriasis. Indian. Dermatol. Online J. 11, 580–585 (2020).
Corren, J. et al. Tezepelumab in adults with uncontrolled asthma. N. Engl. J. Med. 377, 936–946 (2017).
Mullard, A. FDA approves first-in-class TSLP-targeted antibody for severe asthma. Nat. Rev. Drug Discov. 21, 89 (2022).
Simpson, E. L. et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J. Am. Acad. Dermatol. 80, 1013–1021 (2019).
Liu, Y. J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 203, 269–273 (2006).
Zhang, Z. et al. Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. Proc. Natl Acad. Sci. USA 106, 1536–1541 (2009).
Yang, L., Fu, J. & Zhou, Y. Research progress in atopic march. Front. Immunol. 11, 1907 (2020).
Simpson, E. L. et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J. Am. Acad. Dermatol. 74, 491–498 (2016).
Paller, A. S. et al. Etanercept treatment for children and adolescents with plaque psoriasis. N. Engl. J. Med. 358, 241–251 (2008).
Morant, A. V., Jagalski, V. & Vestergaard, H. T. Labeling of disease-modifying therapies for neurodegenerative disorders. Front. Med. 6, 223 (2019).
Laifenfeld, D. et al. Emulated clinical trials from longitudinal real-world data efficiently identify candidates for neurological disease modification: examples from Parkinson’s disease. Front. Pharmacol. 12, 631584 (2021).
Franklin, J. M., Liaw, K. L., Iyasu, S., Critchlow, C. W. & Dreyer, N. A. Real-world evidence to support regulatory decision making: new or expanded medical product indications. Pharmacoepidemiol. Drug Saf. 30, 685–693 (2021).
De, S., Larson, L., Kelly, K., Hanson, B. & Mack, C. D. Leveraging real-world evidence: a paradigm shift in regulation. J. Orthop. Trauma. 35, S13–S16 (2021).
Dreyer, N. A. Strengthening evidence-based medicine with real-world evidence. Lancet Healthy Longev. 3, e641–e642 (2022).
Stolzl, D. et al. Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry. Br. J. Dermatol. 187, 1022–1024 (2022).
FDA. Draft guidance for industry. Indications and usage section of labeling for human prescription drug and biological products — content and format (2018).
European Commission. Notice to applicants. A guideline on Summary of Product Characteristics (SmPC) (2009).
This work was supported by the Christine Kühne-Center for Allergy Research and Education (CK-CARE).
T.B. was speaker and/or consultant and/or investigator for AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Arena, Aristea, Asana Biosciences, ASLAN Pharma, Bayer Health, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DIECE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Evelo, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L’Oréal, MSD, Medac, Micreos, Nektar, Novartis, Numab, OM-Pharma, Overtone, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, UCB and Union Therapeutics. He is the founder and chairman of the board of the non-profit biotech ‘Davos Biosciences’ within the International Kühne-Foundation.
Peer review information
Nature Reviews Drug Discovery thanks Brian Kim, Miriam Wittman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Bio Revolution report from Mc Kinsey: https://www.mckinsey.com/industries/life-sciences/our-insights/the-bio-revolution-innovations-transforming-economies-societies-and-our-lives
EMA Guideline on registry-based studies: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en.pdf
EMA Regulatory Science to 2025: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf; and https://www.ema.europa.eu/en/documents/presentation/presentation-proposal-darwin-eu-data-analytics-real-world-interrogation-network-parlett-ema_en.pdf
FDA, Black box warning on topical calcineurin inhibitors: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-approves-updated-labelling-boxed-warning-and-medication-guide-two-eczema-drugs-elidel-and
FDA, Guidance for Industry, ‘Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products’, September 2022: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products
Framework for FDA’s real-world evidence program: https://www.fda.gov/media/120060/download
Guidance for submitting documents using real-world data and real-world evidence to FDA for drug and biological products: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drug-and-biological-products
Positive CHMP opinion EMA/CHMP/898000/2023: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-sotyktu_en.pdf
Press release from dermatology experts on skin diseases: https://newsroom.submitmypressrelease.com/2022/01/05/top-dermatology-experts-from-across-the-world-unite-to-call-for-comprehensive-action-to-elevating-skin-disease_123684.html
Press release from Nektar Therapeutics: Nektar Therapeutics announces phase 1b data for novel T regulatory stimulator NKTR-358 in patients with atopic dermatitis: https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-phase-1b-data-for-novel-t-regulatory-cell-stimulator-nktr-358-ly3471851-in-patients-with-atopic-dermatitis-301445396.html
Press release from Sanofi: New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis: https://www.sanofi.com/en/media-room/press-releases/2021/2021-09-30-12-30-00-2306183
WHO report on Psoriasis: https://apps.who.int/iris/handle/10665/204417
About this article
Cite this article
Bieber, T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov 22, 662–680 (2023). https://doi.org/10.1038/s41573-023-00735-0